Scholar Rock Holding Corp
$ 44.68
-5.72%
02 Jun - close price
- Market Cap 5,678,665,000 USD
- Current Price $ 44.68
- High / Low $ 47.01 / 44.43
- Stock P/E N/A
- Book Value 2.26
- EPS -3.45
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.54 %
- ROE -1.39 %
- 52 Week High 52.19
- 52 Week Low 27.07
About
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$59.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-03 | 2025-11-14 | 2025-08-06 | 2025-05-14 | 2025-02-27 | 2024-11-12 | 2024-08-08 | 2024-05-07 | 2024-03-19 | 2023-11-07 | 2023-08-09 |
| Reported EPS | -0.83 | -0.88 | -0.9 | -0.98 | -0.67 | -0.61 | -0.66 | -0.6 | -0.59 | -0.5 | -0.53 | -0.47 |
| Estimated EPS | -0.78 | -0.8983 | -0.84 | -0.67 | -0.71 | -0.6288 | -0.6 | -0.59 | -0.51 | -0.49 | -0.51 | -0.55 |
| Surprise | -0.05 | 0.0183 | -0.06 | -0.31 | 0.04 | 0.0188 | -0.06 | -0.01 | -0.08 | -0.01 | -0.02 | 0.08 |
| Surprise Percentage | -6.4103% | 2.0372% | -7.1429% | -46.2687% | 5.6338% | 2.9898% | -10% | -1.6949% | -15.6863% | -2.0408% | -3.9216% | 14.5455% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.84 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRRK
2026-05-27 03:10:12
Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company focused on spinal muscular atrophy (SMA) and other neuromuscular diseases, announced its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation will be webcast live and a replay will be available for approximately 90 days on the company's investor relations website. Scholar Rock is recognized for its leadership in myostatin biology to advance musculoskeletal health.
2026-05-26 15:09:31
Scholar Rock (NASDAQ: SRRK) announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 10:00 a.m. ET. The biopharmaceutical company, focused on treating spinal muscular atrophy (SMA) and other neuromuscular diseases, will make a live webcast of the event available on its Investors section. A replay will be accessible for approximately 90 days following the presentation.
2026-05-26 13:39:32
Scholar Rock announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL. The presentation is scheduled for Tuesday, June 9, 2026, at 10:00 a.m. ET. A live webcast and subsequent replay will be available on the Investors section of Scholar Rock’s website.
2026-05-20 13:38:41
Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company focused on neuromuscular diseases, announced that its management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET. A live webcast and replay of the presentation will be accessible via the Investors section of the company's website. Scholar Rock specializes in developing treatments for spinal muscular atrophy (SMA) and other rare diseases through its myostatin biology platform.
2026-05-20 11:59:35
Scholar Rock (NASDAQ: SRRK) announced that its management will participate in the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET. The company, which specializes in therapies for spinal muscular atrophy and other neuromuscular diseases, will provide a live webcast of the presentation. A replay will also be available on Scholar Rock's investor relations website for approximately 90 days following the event.
2026-05-17 12:09:35
Charles Schwab Investment Management Inc. increased its stake in Scholar Rock Holding Corporation by 3.7% in the fourth quarter, acquiring an additional 25,060 shares, bringing its total holdings to 702,095 shares valued at $30.9 million. Wall Street analysts maintain a generally bullish outlook on SRRK, with a consensus "Buy" rating and an average target price of $56.00. The article also notes recent insider sales by the CEO and CFO, which were attributed to tax withholding obligations related to equity awards.
